- Community Resources
- About Breast Cancer
- Get Involved
Recent Local Successes
Oral Chemotherapy Parity
The Susan G. Komen Affiliates in Ohio worked together with a coalition of patient advocacy organizations to pass Oral Chemotherapy Parity legislation. After years of work, Governor John Kasich signed into law the Oral Chemotherapy bill on June 17th, 2014. This means that patients who are prescribed an orally administered cancer medication will receive as much coverage by their insurance as they would for IV administered cancer medications.
“When facing a cancer diagnosis, patients shouldn’t be put in a position where they have to make decisions on their treatment options based on the price tag of the medications that give them the best chance at saving or prolonging their life. That is what Ohio cancer patients have been facing for the several years we have been working on this bill,” said Julie McMahon, director of mission at Komen Columbus. “We are so thrilled that the women and men facing cancer in Ohio will have the peace of mind that whatever decisions they find are best for them regarding their treatment will be covered fairly by their insurance.”
This victory has been at least three years in the making with the leadership of Senators Scott Oelslager (R) and Charleta B. Tavares (D), along with the collaborative efforts of the American Cancer Society Cancer Action Network, the Leukemia & Lymphoma Society, Cancer Support Community, International Myeloma Foundation and all the Ohio Susan G. Komen Affiliates. We also want to thank more than 385 Komen Advocacy Alliance supporters who helped the cause by writing letters to their House or Senate representatives through our e-alerts.
This bill is important because more than a quarter of the anti-cancer drugs in the research pipeline today are intended as oral drugs. Unfortunately, insurance practices have not kept up with advancements in science. Now, SB99 allows patients and their doctors to review the best possible treatment options based on what is best for the patient- not a price tag of treatment.
Interested in learning more? Read a few of our blog articles on the subject:
The Time has Come to Modernize Coverage for Cancer Treatment
We Have a Chance to Make a Difference in the Lives of Cancer Patients
From Diagnosis to Treatment to the ‘Glimmer of Hope’
The bill will go into effect January 1, 2015.
Medicaid Expansion Brings Access to Prevention and Early Detection to more of Ohio’s Underserved Women
On February 19th, Ohio Governor John Kasich delivered his annual State of the State Address and spoke in detail of his state budget proposal which includes the expansion of Medicaid in Ohio.
Medicaid is a state and federal funded health care program that serves an estimated 2.2 million low-income, elderly and disabled Ohioans. Under the Affordable Care Act, states have the option to expand Medicaid eligibility and receive additional federal funds that would increase access to preventative care and treatment services to hundreds of thousands of uninsured individuals.
We all recognize early detection is the best tool we have in the battle against breast cancer. This is why the Columbus Affiliate of Susan G. Komen for the Cure supports the Governor’s plan to expand Ohio’s Medicaid program.
Tax Check-off Bill Increases Funding for Ohio Breast and Cervical Cancer Program
The Ohio Affiliates of Susan G. Komen® were proud to support House Bill (HB) 112, which will allow Ohio taxpayers to contribute a portion of their tax refund to the Ohio Breast and Cervical Cancer Project (BCCP). BCCP provides breast and cervical cancer screening and diagnostic services to women in Ohio who do not qualify for Medicaid, between 100% and 200% of the Federal Poverty Level. The bill was signed into law July 11, 2013 and contributions can be made for the tax year beginning January 1, 2014.
Ohio’s BCCP, funded at the current levels, is only able to serve about 5% of the eligible women in Ohio. The BCCP Tax Check-Off will enable the program to serve up to 1,700 additional women (approximately an 11% increase) with life saving and cost saving access to early detection and diagnostics.